Similarly, Kingwell et al. (15) identified a 4.4% cancer incidence in patients treated with interferon beta, predominantly involving breast, lung, and prostate cancers (15) – but the latter two were not reported in our investigation. Here, IFNB1 is linked to prostate carcinoma.